Compare Amphastar Pharmaceuticals Inc (AMPH) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs VICI Properties Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while VICI Properties Inc trades at $26.11 (market cap $28.64B). The key difference: VICI Properties Inc is far larger — about 34.7× Amphastar Pharmaceuticals Inc's market cap, and VICI Properties Inc pays a 6.92% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | VICI | |
|---|---|---|
Market Cap | $826.08M | $28.64B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $33.93 |
52-Week Low | $16.87 | $25.94 |
Enterprise Value | $1.22B | $45.86B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VICI Properties trades at $26.01, showing modest daily gains. The stock is technically bearish with key support at $25, while fundamentals remain strong with a P/E of 8.91 and robust profitability margins. Recent news highlights concerns over tenant concentration but also underscores the REIT's investment-grade balance sheet and attractive 6.8% dividend yield. Q2 2026 earnings are anticipated on July 29, 2026.
The outlook is mixed: strong cash flows and analyst buy ratings support upside to a $30.75 target, but technical weakness and reliance on Caesars/MGM pose risks. Investors may find value in the discounted valuation if operational stability persists amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
